Clinical Trial Update: Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial investigated whether depleting regulatory T cells with CSA could enhance cetuximab efficacy in advanced head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CSA (cyclosporine A)
• Cetuximab (cetuximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-11